HALOPERIDOL DECANOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C31H41ClFNO3
Molecular Weight	530.114
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Cl)C=C3

InChI

InChIKey=GUTXTARXLVFHDK-UHFFFAOYSA-N

InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00502
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14611858	Inverse Agonist 80	17.0 nM [EC50]
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00502	Antagonist 2778
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7520908	Antagonist 2778	53.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 8429	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 1986
Tourette's syndrome 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 8429	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 1986

Doses

Dose	Population	Adverse events
0.9 mg single, oral Overdose Dose: 0.9 mg Route: oral Route: single Dose: 0.9 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28128816	unknown, 11 years n = 1 Health Status: unknown Age Group: 11 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28128816	Other AEs: Drowsiness... Other AEs: Drowsiness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28128816
2 mg 4 times / day multiple, intramuscular Recommended Dose: 2 mg, 4 times / day Route: intramuscular Route: multiple Dose: 2 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: dementia-related psychosis Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf
5 mg 3 times / day multiple, oral Recommended Dose: 5 mg, 3 times / day Route: oral Route: multiple Dose: 5 mg, 3 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6	unhealthy, adult Health Status: unhealthy Condition: dementia-related psychosis Age Group: adult Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6	Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6
10 mg 2 times / day steady, intravenous Dose: 10 mg, 2 times / day Route: intravenous Route: steady Dose: 10 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01211522	unhealthy n = 192 Health Status: unhealthy Condition: Delirium Population Size: 192 Sources: https://clinicaltrials.gov/ct2/show/NCT01211522	Other AEs: Torsades de pointes, Electrocardiogram QTc interval prolonged... Other AEs: Torsades de pointes (serious, 2 patients) Electrocardiogram QTc interval prolonged (below serious, 13 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01211522
10 mg 2 times / day steady, oral Dose: 10 mg, 2 times / day Route: oral Route: steady Dose: 10 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00129220	unhealthy n = 20 Health Status: unhealthy Condition: Bipolar I Disorder Population Size: 20 Sources: https://clinicaltrials.gov/ct2/show/NCT00129220	Other AEs: Cheilitis, Constipation... Other AEs: Cheilitis (below serious, 1 patient) Constipation (below serious, 2 patients) Salivary hypersecretion (below serious, 1 patient) Vomiting (below serious, 1 patient) Malaise (below serious, 2 patients) Thirst (below serious, 1 patient) Fall (below serious, 1 patient) Blood pressure decreased (below serious, 1 patient) Weight increased (below serious, 1 patient) Increased appetite (below serious, 1 patient) Arthralgia (below serious, 1 patient) Osteoarthritis (below serious, 1 patient) Akathisia (below serious, 3 patients) Dystonia (below serious, 3 patients) Headache (below serious, 1 patient) Sedation (below serious, 1 patient) Tremor (below serious, 2 patients) Depressive symptom (below serious, 1 patient) Insomnia (below serious, 1 patient) Mania (below serious, 1 patient) Pruritus (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00129220

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inhibitor 1767	substrate 1217 activator 23 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2J2 16 P-gp 1461 OCT1 512 BCRP 699 MRP2 383 MDR3 8 Kv4.3 16 CYP1A2 1524 CYP2A6 707 CYP2C8 911 CYP2C19 1478 CYP2E1 882 BSEP 402 MRP3 157 MRP4 204 OATP1B1 788 OATP1B3 706	CYP1A2 1054 CYP1A1 349 CYP2C8 693 CYP2C19 991 CYP3A5 395 UGT 192 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A9 380 UGT2B7 389 UGT2B15 203 P-gp 1537 OCT1 327 MATE1 135

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1891	inhibitor 3277 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3 \| https://pubmed.ncbi.nlm.nih.gov/10460810/	moderate [Ki 7.2 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://pubmed.ncbi.nlm.nih.gov/18457386/	no [IC50 >133 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	no [IC50 >30 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://pubmed.ncbi.nlm.nih.gov/23033255/	no [IC50 >50 uM]
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	yes [Activation 31.6228 uM]
MDR3 9	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/26335978/	yes [IC50 10.7 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	yes [IC50 141.9 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 2.87 uM]
BSEP 403	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891329/, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 25.3 uM]
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16810505/	yes [IC50 25.4 uM]
Kv4.3 16	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/24998874/	yes [IC50 3.6 uM]
CYP2J2 19	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23033255/	yes [IC50 4.69 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 8.2 uM]
CYP2D6 1891	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/9681669/, https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000052868	yes
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12031686/	likely [Km 33 uM]
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=8 Page: (Label) 8, 27	major
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	major
CYP2D6 1217	substrate 3367 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of CYP2D6 inhibitors (chlorpromazine, promethazine, quinidine, paroxetine, sertraline, venlafaxine) increased Haloperidol plasma concentrations. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP3A4 1737	substrate 3367 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of Rifampicin (strong CYP3A4 inducer) decreased plasma Haloperidol levels by a mean of 70%. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP1A2 1054	substrate 3367 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null	minor
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT2B15 203	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
CYP1A1 349	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
MATE1 135	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/18448342/, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1038/sj.bjp.0705025 Page: (Label) 9, 28

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5613	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5613
ChemicalBook	CB32131152	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32131152
ChemicalBook	CB72509133	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72509133
ChemicalBook	CB7774829	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7774829
MolPort	MolPort-000-883-311	https://www.molport.com/shop/molecule-link/MolPort-000-883-311
Selleck Chemicals	Haloperidol(Haldol)	http://www.selleckchem.com/products/Haloperidol(Haldol).html
ZINC	ZINC000000537822	http://zinc15.docking.org/substances/ZINC000000537822
eMolecules	538987	https://www.emolecules.com/cgi-bin/more?vid=538987

PubMed

Title	Date	PubMed
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.	1975 Aug 21	1103205
Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat.	1976 Jul	1033561
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?	1999	10651103
Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors.	1999	10613497
Antipsychotic profile of alstonine: ethnopharmacology of a traditional Nigerian botanical remedy.	1999	10412490
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep.	1999 Apr	10459715
Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice.	1999 Aug	10494572
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.	1999 Dec	10628507
Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation.	1999 Feb	10780307
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.	1999 Jul	10468314
Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.	1999 Jul	10379522
Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation.	1999 Jun	10435392
New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.	1999 Jun	10435384
Tardive dystonia induced by risperidone.	1999 Jun	10389620
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.	1999 Jun	10350027
The effects of benzamide analogues on cocaine self-administration in rhesus monkeys.	1999 Nov	10591881
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.	1999 Nov	10591873
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.	1999 Nov 26	10594343
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.	1999 Oct	10589449
Haloperidol-induced torsade de pointes.	1999 Oct	10534216
Hypotension associated with clozapine after cardiopulmonary bypass.	1999 Oct	10527233
Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.	1999 Oct 8	10528146
Two additional uses for sildenafil in psychiatric patients.	1999 Oct-Dec	10546163
Detection and mapping of quantitative trait loci for haloperidol-induced catalepsy in a C57BL/6J x DBA/2J F2 intercross.	1999 Sep	10765558
A case of leukocytoclastic vasculitis associated with haloperidol.	1999 Sep	10564343
Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.	1999 Sep	10495006
Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14.	1999 Sep	10454512
Effect of muscarinic receptor agonists on animal models of psychosis.	2000 Apr	10893700
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.	2000 Apr	10780978
Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs.	2000 Dec	11166067
Prolonged upper airway instability in the parenteral use of benzodiazepine with levomepromazine.	2000 Feb	10653217
Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.	2000 Jan	10672628
Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration.	2000 Jan 21	10670778
Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex.	2000 Jan 28	10698007
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.	2000 Jan 3	10661492
Manic episode in an ifosfamide-treated patient.	2000 Jan-Feb	10766557
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.	2000 Jul	10871703
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.	2000 Jul	10869885
[Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].	2000 Jul-Aug	11064842
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.	2000 Mar	10744342
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.	2000 Mar	10730737
Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.	2000 Mar 10	10720636
Effects of blockade of metabotropic glutamate receptors in the subthalamic nucleus on haloperidol-induced Parkinsonism in rats.	2000 Mar 17	10713387
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.	2000 May	10888308
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.	2000 May	10868556
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.	2000 May	10847307
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.	2000 Nov	11071396
Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation.	2000 Sep	10974607
Haloperidol-induced impotence improved by switching to olanzapine.	2000 Sep-Oct	11203037
Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.	2001 Feb	11156818

Patents

Sample Use Guides

In Vivo Use Guide

Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.

Route of Administration: Intramuscular

In Vitro Use Guide

10 uM Haloperidol induced a 54% decrease in the mRNA expression of ABCA1 in murineperitoneal macrophages.

Name

Type

Language

HALOPERIDOL DECANOATE

Official Name

English

HALOPERIDOL DECANOATE [MI]

Common Name

English

R-13672

Code

English

HALOPERIDOL DECANOATE [JAN]

Common Name

English

HALOPERIDOL DECANOATE [USAN]

Common Name

English

HALOPERIDOL DECANOATE [USP-RS]

Common Name

English

HALOPERIDOL DECANOATE [MART.]

Common Name

English

HALOPERIDOL DECANOATE [EP MONOGRAPH]

Common Name

English

DECANOIC ACID, ESTER WITH 4-(4-(P-CHLOROPHENYL)-4-HYDROXYPIPERIDINO)-4'-FLUOROBUTYROPHENONE

Common Name

English

HALOPERIDOL DECANOATE [EP IMPURITY]

Common Name

English

HALOPERIDOL DECANOATE [USP IMPURITY]

Common Name

English

Haloperidol decanoate [WHO-DD]

Common Name

English

R-13,672

Code

English

DECANOIC ACID, 4-(4-CHLOROPHENYL)-1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-4-PIPERIDINYL ESTER

Common Name

English

HALOPERIDOL DECANOATE [USP MONOGRAPH]

Common Name

English

HALOPERIDOL DECANOATE [ORANGE BOOK]

Common Name

English

HALOMONTH

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883